Kidney disease may change how stiripentol works

NCT ID NCT05735951

Completed Knowledge-focused Sponsor: Biocodex Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed phase 1 study looked at how the drug stiripentol behaves in people with mild, moderate, or severe chronic kidney disease compared to those with normal kidney function. Thirty-nine participants took stiripentol by mouth for 15 days. The goal was to see if kidney impairment alters drug levels in the blood, which could help determine if dose adjustments are needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stiripentol
What this could lead to: If successful, this study could help doctors adjust stiripentol doses for people with kidney problems, making the drug safer and more effective for them.
What could go wrong: This is a small, early-phase study focused on drug levels, not on treating any disease. Results may not change clinical practice without larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RENAL INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RENAL INSUFFICIENCY

Contacts and locations

Locations

Mc Comac Medical

Sofia, 1612, Bulgaria

More trials for these conditions

Other studies related to the condition(s) this trial covers.